Tag: Duchenne muscular dystrophy

Sarepta Therapeutics saw its share price dip on Thursday after regulators requested more work be done before approval of final-phase testing for a treatment for Duchenne muscular dystrophy. Analysts generally viewed the action of the U.S. Food and Drug Administration as a minor delay. SVB Leerink analyst Joseph Schwartz has maintained an outperform rating on … Continue reading “Sarepta Therapeutics Shares Crumble After Regulators Request More Work to Be Done”